Therapeutic approaches for FAM83G-associated palmoplantar keratoderma (PPK) remain largely symptomatic, as there are currently no targeted molecular therapies described in the literature for this condition, as far as we know. This evidence concerns the gene SACK1G and epidermolytic palmoplantar keratoderma, 1.